Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vivek Subbiah

Showing results (261-270 of 487) with videos related to

Pageof 49
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
Real-World Biomarker-Associated Therapy in Metastatic Carcinoma of Unknown Primary: Prevalence, Impact, and OutcomesDipesh Uprety, Kieran Sweeney, Lubina Arjyal, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2024
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid CarcinomaSarah Hamidi, Sireesha Yedururi, Mimi I Hu, et al.
Journal of Medicinal Chemistry|December 26, 2024
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the ProteinYafeng Wang, Xueqing Hu, Shriya Pandey, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2018
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvementElena Fountzilas, Elangovan Krishnan, Filip Janku, et al.
British Journal of Cancer|April 26, 2017
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinomaRachna T Shroff, Mark Yarchoan, Ashley O'Connor, et al.
Diagnosis (Berlin, Germany)|April 10, 2023
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicineDenis Horgan, Ettore Capoluongo, France Dube, et al.
The Oncologist|September 15, 2021
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 TrialAnna Minchom, Aaron C Tan, Erminia Massarelli, et al.
Investigational New Drugs|September 1, 2021
A phase i study of ixazomib and erlotinib in patients with advanced solid tumorsShumei Kato, Jacob J Adashek, Vivek Subbiah, et al.
JCO Global Oncology|February 4, 2026
Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug DevelopmentDenis Horgan, Zorana Maravic, Ken Mastris, et al.
Cancer|November 7, 2023
Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databasesFrank Griesinger, Sreeram Ramagopalan, Winson Y Cheung, et al.
Pageof 49

Showing results (261-270 of 487) with videos related to

Sort By:
Pageof 49
Journal of the National Comprehensive Cancer Network : JNCCN|March 30, 2026
Real-World Biomarker-Associated Therapy in Metastatic Carcinoma of Unknown Primary: Prevalence, Impact, and OutcomesDipesh Uprety, Kieran Sweeney, Lubina Arjyal, et al.
Thyroid : Official Journal of the American Thyroid Association|December 4, 2024
Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid CarcinomaSarah Hamidi, Sireesha Yedururi, Mimi I Hu, et al.
Journal of Medicinal Chemistry|December 26, 2024
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the ProteinYafeng Wang, Xueqing Hu, Shriya Pandey, et al.
Cancer Chemotherapy and Pharmacology|September 6, 2018
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvementElena Fountzilas, Elangovan Krishnan, Filip Janku, et al.
British Journal of Cancer|April 26, 2017
The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinomaRachna T Shroff, Mark Yarchoan, Ashley O'Connor, et al.
Diagnosis (Berlin, Germany)|April 10, 2023
Clouds across the new dawn for clinical, diagnostic and biological data: accelerating the development, delivery and uptake of personalized medicineDenis Horgan, Ettore Capoluongo, France Dube, et al.
The Oncologist|September 15, 2021
Patient-Reported Outcomes with Selpercatinib Among Patients with RET Fusion-Positive Non-Small Cell Lung Cancer in the Phase I/II LIBRETTO-001 TrialAnna Minchom, Aaron C Tan, Erminia Massarelli, et al.
Investigational New Drugs|September 1, 2021
A phase i study of ixazomib and erlotinib in patients with advanced solid tumorsShumei Kato, Jacob J Adashek, Vivek Subbiah, et al.
JCO Global Oncology|February 4, 2026
Global Trials, Local Relevance: A Scientific and Regulatory Framework for Regional Enrollment in Cancer Drug DevelopmentDenis Horgan, Zorana Maravic, Ken Mastris, et al.
Cancer|November 7, 2023
Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databasesFrank Griesinger, Sreeram Ramagopalan, Winson Y Cheung, et al.
Pageof 49